Literature DB >> 12750118

Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.

Amir F Ayyobi1, Sandra H McGladdery, Marguerite J McNeely, Melissa A Austin, Arno G Motulsky, John D Brunzell.   

Abstract

OBJECTIVE: Familial combined hyperlipidemia (FCHL) is associated with variable lipid and lipoprotein phenotypes arbitrarily defined as type IIa, IIb, and IV based on plasma total cholesterol and triglyceride levels. This study sought to characterize consistent lipoprotein and lipid abnormalities across the 3 lipoprotein phenotypes in 62 patients with documented FCHL (IIa [n=14], IIb [n=19], and IV [n=29]) and 44 healthy individuals. METHODS AND
RESULTS: The lipoprotein cholesterol distribution was determined over 38 fractions obtained by density gradient ultracentrifugation. As expected, FCHL patients with hypertriglyceridemia (IIb and IV) had higher cholesterol levels in VLDL than IIa, whereas IIa showed higher cholesterol in the big, buoyant LDL and in HDL. LDL cholesterol was higher in IIb than IV; most of the increase in LDL cholesterol was associated with big, buoyant LDL rather than small, dense LDL (sdLDL). The differences in lipoproteins between phenotypes were attributable to changes in VLDL and big, buoyant LDL levels. Comparison of the FCHL patients with healthy individuals showed a significant elevation in plasma apolipoprotein B levels and sdLDL in all 3 FCHL phenotypes.
CONCLUSIONS: Although triglyceride and cholesterol levels are variable by lipoprotein phenotype, sdLDL and elevated plasma apolipoprotein B levels are consistent characteristics of FCHL shared by the 3 different lipoprotein phenotypes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750118     DOI: 10.1161/01.ATV.0000077220.44620.9B

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

Review 1.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

Review 2.  Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Anton Stalenhoef
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-10-17       Impact factor: 4.690

3.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

4.  Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.

Authors:  Roberto Ferrari; Carlos Aguiar; Eduardo Alegria; Riccardo C Bonadonna; Francesco Cosentino; Moses Elisaf; Michel Farnier; Jean Ferrières; Pasquale Perrone Filardi; Nicolae Hancu; Meral Kayikcioglu; Alberto Mello E Silva; Jesus Millan; Željko Reiner; Lale Tokgozoglu; Paul Valensi; Margus Viigimaa; Michal Vrablik; Alberto Zambon; José Luis Zamorano; Alberico L Catapano
Journal:  Eur Heart J Suppl       Date:  2016-04-12       Impact factor: 1.803

Review 5.  Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Authors:  Michel R Langlois; Børge G Nordestgaard
Journal:  Curr Cardiol Rep       Date:  2018-08-17       Impact factor: 2.931

6.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

Review 7.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

8.  Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.

Authors:  Alberto Zambon; Xue-Qiao Zhao; B Greg Brown; John D Brunzell
Journal:  Am J Cardiol       Date:  2014-02-11       Impact factor: 2.778

9.  Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene.

Authors:  Antonio López-Ruiz; María M Jarabo; María L Martínez-Triguero; Maria Morales-Suárez-Varela; Eva Solá; Celia Bañuls; Marta Casado; Antonio Hernández-Mijares
Journal:  Lipids Health Dis       Date:  2009-03-31       Impact factor: 3.876

10.  A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia.

Authors:  Adriana Huertas-Vazquez; Christopher L Plaisier; Ruishuang Geng; Blake E Haas; Jenny Lee; Marleen M Greevenbroek; Carla van der Kallen; Tjerk W A de Bruin; Marja-Riitta Taskinen; Kumar N Alagramam; Päivi Pajukanta
Journal:  Hum Genet       Date:  2009-10-09       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.